P548: BEMCENTINIB COMBINED WITH LOW‐DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)

P548: BEMCENTINIB COMBINED WITH LOW‐DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)

Saved in:
Bibliographic Details
Published in:HemaSphere Vol. 6; pp. 447 - 448
Main Authors: Loges, S., Heuser, M., Chromik, J., Sutamtewagul, G., Kapp‐Schwoerer, S., Crugnola, M., Di Renzo, N., Lemoli, R., Mattei, D., Ben‐Batalla, I., Waizenegger, J., Rieckmann, L.‐M., Janning, M., Imbusch, C. D., Beumer, N., Micklem, D., Gorcea‐Carson, C., Lawson, G., Nautiyal, J., Deharo, S., Fiedler, W., Alvarado‐Valero, Y., Gjertsen, B.
Format: Journal Article
Language:English
Published: Philadelphia, PA Lippincott Williams & Wilkins 23-06-2022
Wiley
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000845080.27665.da